©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Aug 15, 2018; 9(8): 138-140
Published online Aug 15, 2018. doi: 10.4239/wjd.v9.i8.138
Published online Aug 15, 2018. doi: 10.4239/wjd.v9.i8.138
Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?
Hidetaka Hamasaki, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Kagoshima 890-0046, Japan
Author contributions: Hamasaki H wrote the review.
Conflict-of-interest statement: No conflict of interest.
Correspondence to: Hidetaka Hamasaki, MD, PhD, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 890-0046, Japan. hhamasaki78@gmail.com
Telephone: +81-99-2503535 Fax: +81-99-2501470
Received: June 4, 2018
Peer-review started: June 4, 2018
First decision: June 14, 2018
Revised: June 20, 2018
Accepted: June 28, 2018
Article in press: June 28, 2018
Published online: August 15, 2018
Processing time: 73 Days and 1.1 Hours
Peer-review started: June 4, 2018
First decision: June 14, 2018
Revised: June 20, 2018
Accepted: June 28, 2018
Article in press: June 28, 2018
Published online: August 15, 2018
Processing time: 73 Days and 1.1 Hours
Core Tip
Core tip: The impact of exercise on glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes (T2D) remains unclear. Exercise could potentiate the effect of GLP-1 receptor agonists treatment and play a vital role in ameliorating GLP-1 resistance by improving gut microbiota dysbiosis and reducing the ectopic fat in patients with T2D.